Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512291 | 0.83 | POLB (0.47) | POLBHCAR2SMN1; SMN2HTTMAPT | |
| SCHEMBL1749636 | 0.82 | KMT2A (0.56) | POLBSMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL22105710 | 0.81 | RAB9A (0.41) | POLBHCAR2SMN1; SMN2HTTMAPT | |
| SCHEMBL16619756 | 0.81 | LMNA (0.40) | KDM4ELMNAKMT2AHPGDRAB9A | |
| SCHEMBL17693545 | 0.80 | CYP11B2 (0.46) | POLBHCAR2SMN1; SMN2HTTMAPT | |
| SCHEMBL5152701 | 0.79 | HTR2C (0.40) | POLBHCAR2SMN1; SMN2HTTMAPT | |
| SCHEMBL7669950 | 0.79 | KDM4E (0.38) | POLBHCAR2SMN1; SMN2HTTMAPT | |
| SCHEMBL16619604 | 0.79 | LMNA (0.39) | LMNAKMT2AHPGDRAB9ANPC1 | |
| SCHEMBL3723569 | 0.78 | CHRNB2 (0.47) | POLBHCAR2SMN1; SMN2HTTMAPT | |
| SCHEMBL16619125 | 0.78 | LMNA (0.38) | LMNAKMT2AHPGDRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526216-B1 | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | PHARMASUM THERAPEUTICS AS (NO) | 2024-04-03 | — | — | EP | disclosed |
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS (NO) | 2021-02-23 | — | — | US | disclosed |
| US-10759799-B2 | Indazole containing macrocycles and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3526216-A1 | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | Pharmasum Therapeutics AS (NO) | 2019-08-21 | — | — | EP | disclosed |
| EP-3052099-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018069468-A1 | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | PHARMASUM THERAPEUTICS AS (NO) | 2018-04-19 | — | — | WO | disclosed |
| US-9486448-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | US | disclosed |
| EP-3052099-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050798-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | DYRK1A, DYRK1B, PDK2 | POLB 2360/4885HCAR2 1840/4885SMN1; SMN2 2813/4885 |
| US-10759799-B2 | Indazole containing macrocycles and therapeutic uses thereof | WNT1, WNT3, WNT3A | POLB 3283/4885HCAR2 3413/4885SMN1; SMN2 2883/4885 |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | POLB 1209/4885HCAR2 328/4885SMN1; SMN2 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.